aTYR PHARMA INC — Director's Dealing 2021

Feb 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2021-02-06

Reporting Person: Shukla Sanjay (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-06	Common stock	M	1785	—	Acquired	9076	Direct
2021-02-09	Common stock	S	778	$7.66	Disposed	8298	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-06	Restricted Stock Unit	$	M	1785	Disposed		Common Stock (1785)	Direct

Footnotes

F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 6, 2019.

F4: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020.